英国肾嗜酸细胞瘤当代手术管理及结局
基于英国泌尿外科医师协会肾切除登记库2013至2016年数据,共1202例肾嗜酸细胞瘤(占32 130例肾手术的3.7%)。多数为男性(62.9%),中位年龄66.8岁,中位病灶4.1 cm;仅2.9%行术前活检,56.8%行根治性肾切除,40.2%行部分肾切除。20.2%出现院内并发症,4%为Clavien-Dindo≥III级,包括3例死亡,术后60天内另有2例死亡。结论认为手术并发症不可忽视,集中化服务和增加活检可能减少过度治疗。
要点
- 肾嗜酸细胞瘤手术以根治性肾切除为主(56.8%),部分肾切除占40.2%。
- 术前活检使用率仅2.9%,可能影响良性肿瘤的术前鉴别。
- 院内并发症发生率20.2%,Clavien-Dindo≥III级占4%。
核心结论
- 英国肾嗜酸细胞瘤手术并发症率不可忽视,集中化专科服务和增加活检可能改善管理并减少过度治疗。
研究设计与样本
- 对BAUS肾切除登记库2013年1月1日至2016年12月31日最终病理诊断为嗜酸细胞瘤的患者进行描述性分析,术后短期结局随访60天。
主要发现
- 4年内英国共记录32 130例肾手术,其中1202例为嗜酸细胞瘤(3.7%)。
- 多数患者为男性(756例;62.9%),中位(IQR)年龄66.8(13)岁。
- 中位(IQR;范围)病灶大小4.1(3;1-25)cm,43.5%病灶≤4 cm,30.3%为4-7 cm。
- 35例(2.9%)行术前肾肿瘤活检;根治性肾切除683例(56.8%),部分肾切除483例(40.2%),其他手术36例(3%)。
- 243例(20.2%)出现院内并发症,其中48例为Clavien-Dindo≥III级(占总队列4%),包括3例死亡;术后60天内另有2例死亡。
临床怎么用
- 对疑似肾嗜酸细胞瘤应提高术前活检使用率以辅助鉴别诊断。
- 手术决策需权衡良性肿瘤性质与根治性肾切除及并发症风险。
- 可考虑集中化专科服务以优化肾嗜酸细胞瘤的管理结局。
局限性
- 观察性研究设计。
- 未纳入监测或活检后消融的病灶。
- 可能存在漏报。
- 随访时间短。
- 缺乏中心病理复核。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report on the contemporary UK experience of surgical management of renal oncocytomas. PATIENTS AND METHODS: Descriptive analysis of practice and postoperative outcomes of patients with a final histological diagnosis of oncocytoma included in The British Association of Urological Surgeons (BAUS) nephrectomy registry from 01/01/2013 to 31/12/2016. Short-term outcomes were assessed over a follow-up of 60 days. RESULTS: Over 4 years, 32 130 renal surgical cases were recorded in the UK, of which 1202 were oncocytomas (3.7%). Most patients were male (756; 62.9%), the median (interquartile range [IQR]) age was 66.8 (13) years. The median (IQR; range) lesion size was 4.1 (3; 1-25) cm, 43.5% were ≤4 cm and 30.3% were 4-7 cm lesions. In all, 35 patients (2.9%) had preoperative renal tumour biopsy. Most patients had minimally invasive surgery, either radical nephrectomy (683 patients; 56.8%), partial nephrectomy (483; 40.2%) or other procedures (36; 3%). One in five patients (243 patients; 20.2%) had in-hospital complications: 48 were Clavien-Dindo classification grade ≥III (4% of the total cohort), including three deaths. Two additional deaths occurred within 60 days of surgery. The analysis is limited by the study's observational nature, not capturing lesions on surveillance or ablated after biopsy, possible underreporting, short follow-up, and lack of central histology review. CONCLUSION: We report on the largest surgical series of renal oncocytomas. In the UK, the complication rate associated with surgical removal of a renal oncocytoma was not negligible. Centralisation of specialist services and increased utilisation of biopsy may inform management, reduce overtreatment, and change patient outcomes for this benign tumour.
引用
- Neves JB, Withington J, Fowler S, et al. Contemporary surgical management of renal oncocytoma: a nation's outcome. BJU Int. 2018. PMID: 29397002. doi:10.1111/bju.14159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。